Patents by Inventor Lieven Lagae
Lieven Lagae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230103644Abstract: The invention relates to 8-hydroxyquinolines or pharmaceutically acceptable salt thereof for use in the prevention or treatment of epilepsy.Type: ApplicationFiled: March 16, 2021Publication date: April 6, 2023Inventors: Bruno Cammue, Peter De Witte, Lieven Lagae, Karin Thevissen
-
Publication number: 20220193082Abstract: Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.Type: ApplicationFiled: January 19, 2022Publication date: June 23, 2022Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Peter De Witte, Lieven Lagae, Jo Sourbron, Bradley S. Galer
-
Publication number: 20220160727Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: February 8, 2022Publication date: May 26, 2022Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Publication number: 20210121479Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: June 12, 2020Publication date: April 29, 2021Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Publication number: 20200030341Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: October 8, 2019Publication date: January 30, 2020Applicants: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Patent number: 10478442Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: GrantFiled: February 10, 2017Date of Patent: November 19, 2019Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten Ceulemens, Lieven Lagae
-
Patent number: 10478441Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: GrantFiled: February 10, 2017Date of Patent: November 19, 2019Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten Ceulemens, Lieven Lagae
-
Publication number: 20180325909Abstract: Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.Type: ApplicationFiled: May 25, 2018Publication date: November 15, 2018Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Peter De Witte, Lieven Lagae, Jo Sourbron, Bradley S. Galer
-
Publication number: 20170151214Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Applicants: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Publication number: 20170151213Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Applicants: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Publication number: 20170151194Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Applicants: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Publication number: 20170151259Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Applicants: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Publication number: 20170151257Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Applicants: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten CEULEMENS, Lieven LAGAE
-
Patent number: 9610260Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: GrantFiled: July 30, 2014Date of Patent: April 4, 2017Assignees: The Katholieke Universiteit Leuven, University Hospital AntwerpInventors: Berten Ceulemens, Lieven Lagae
-
Patent number: 9603815Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: GrantFiled: January 21, 2016Date of Patent: March 28, 2017Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten Ceulemens, Lieven Lagae
-
Patent number: 9603814Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: GrantFiled: July 30, 2014Date of Patent: March 28, 2017Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten Ceulemens, Lieven Lagae
-
Publication number: 20170071949Abstract: Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.Type: ApplicationFiled: September 14, 2016Publication date: March 16, 2017Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Peter DE WITTE, Lieven LAGAE, Jo SOURBRON, Bradley S. GALER
-
Patent number: 9549909Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: GrantFiled: May 3, 2013Date of Patent: January 24, 2017Assignees: The Katholieke Universiteit Leuven, University Hospital AntwerpInventors: Berten Ceulemens, Lieven Lagae
-
Publication number: 20160136114Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: January 21, 2016Publication date: May 19, 2016Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERPInventors: Berten Ceulemens, Lieven Lagae
-
Publication number: 20140343162Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: July 30, 2014Publication date: November 20, 2014Inventors: Berten Ceulemens, Lieven Lagae
